ReachMD

Dr Mikkael A. Sekeres earned a medical degree and a master’s degree in clinical epidemiology from the University of Pennsylvania School of Medicine in Philadelphia. He completed his postgraduate training at Harvard University, finishing an internal medicine residency at Massachusetts General Hospital and a fellowship in hematology–oncology at the Dana-Farber Cancer Institute in Boston. Dr Sekeres chaired the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration and is chair of the medical advisory board of the Aplastic Anemia and Myelodysplastic Syndrome (MDS) International Foundation, the MDS Research Fund of the Dresner Foundation, and the Cleveland Clinic Enterprise Pharmacy & Therapeutics Committee. An invited speaker at numerous meetings, grand rounds, and conferences, Dr Sekeres is a member of the American Society of Hematology (ASH) and serves on the society’s executive committee. He is also a member of the American Society of Clinical Oncology and the Southwest Oncology Group–Leukemia Committee. His research focuses on patients with MDS and older adults with acute myeloid leukemia, and he has been the national and international primary study investigator on several phase 1, 2, and 3 trials. Dr Sekeres is the author or coauthor of more than 350 manuscripts and 550 abstracts published in leading journals such as The New England Journal of Medicine, Blood, Journal of Clinical Oncology, Nature Genetics, Cancer Cell, Journal of the National Cancer Institute, Journal of Clinical Investigation, PLoS One, and Leukemia. He was the inaugural editor-in-chief of the ASH Clinical News magazine, is on the editorial boards of several journals, has written more than 50 essays for The New York Times, and has authored 7 books, including When Blood Breaks Down: Life Lessons From Leukemia, published by MIT Press in March, 2020.